4D Molecular (FDMT) Therapeutics announced that on January 13, 2026, the compensation committee of the Company’s board of directors granted four new non-executive employees 23,600 Restricted Stock Units, RSUs. The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- 4D Molecular Therapeutics Expands Leadership With New Director Appointment
- 4D Molecular Therapeutics: Encouraging Early CF Gene Therapy Signals Tempered by Limited Data, Supporting a Neutral Hold Rating
- 4D Molecular announces interim data from 4D-710 Phase 1 AEROW trial
- 4D Molecular Therapeutics Expands Phase 3 Trial Enrollment